We have shown that targeting T cells against tumor-related lipid antigens presented by CD1c are a viable immunotherapy strategy for hematological malignancies, which are driven by the pathological counterpart of the cells that normally express CD1 group 1 molecules. This evidence concerns the gene CD1C and hematologic disorder.